CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP. Type a few symbols and Take a Trial. The signals for these will appear ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds. Rising interest rates, challenges in the U.S. healthcare system, and the ...

Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the March 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

As health secretary, RFK Jr. said he would divest interests in several companies—including CRISPR Therapeutics and Dragonfly Therapeutics—within 90 days, according to a Jan. 21 disclosure ...

Vertex Pharmaceuticals, best known for its breakthrough cystic fibrosis (CF) treatments, is to become one of the first partners of CRISPR Therapeutics, a leader in new gene-editing technology.